4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-038126
President & Immunovant CEO sold 125,667 shares at an average $16.29 ($2,047,336)
- President & Immunovant CEO acquired 125,667 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Venker Eric · President & Immunovant CEO
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-09 | Exercise or conversion : show line 1 in the form 10b5-1 | +104,940 | $15.85 | $1,663,299 | 1,609,899 | D |
| 2025-10-09 | Sale : show line 2 in the form 10b5-1 | −104,940 | $16.30 | $1,710,522 | 1,504,959 | D |
| 2025-10-13 | Exercise or conversion : show line 3 in the form 10b5-1 | +20,727 | $15.85 | $328,523 | 1,525,686 | D |
| 2025-10-13 | Sale : show line 4 in the form 10b5-1 | −20,727 | $16.25 | $336,814 | 1,504,959 | D |
| Open-market sales · 125,667 sh · avg $16.29 · $2,047,336 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-10-09 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −104,940 | 872,110 | D |
| 2025-10-13 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) | −20,727 | 851,383 | D |
Loading xslF345X05/form4.xml…